TargetBeta
BRAF
B-Raf proto-oncogene, serine/threonine kinase · also BRAF1, BRAF-1 · Mitogen-activated protein kinase kinase kinases
5 programs in company-led studies act on BRAF, from 5 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 404 running | ABL1, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | ChEMBL |
| tovorafenibrule | Day One Biopharmaceuticals | phase 3 | 83 running | ARAF, RAF1 | ChEMBL |
| BRAF V600E Inhibitor HLX208 | Fosun Pharma | phase 2 | 127 running | – | the company's pipeline |
| belvarafenibrule | Hanmi Pharmaceutical | phase 2 | 64 running | ARAF, RAF1 | ChEMBL |
| claturafenib | Pfizer | phase 1 | 21 running | – | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Melanoma, 3 programs
- Colorectal Neoplasms, 2 programs
- Neoplasms, 2 programs
- Brain Neoplasms, 1 program
- Carcinoma, Hepatocellular, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Histiocytosis, Langerhans-Cell, 1 program
- Neoplasm Metastasis, 1 program
- Pancreatic Neoplasms, 1 program
- Squamous Cell Carcinoma of Head and Neck, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2026belvarafenib · Hanmi Pharmaceutical · phase 2 · NCT04835805
- May 31, 2027tovorafenib · Day One Biopharmaceuticals · phase 3 · NCT04775485
- Aug 31, 2027claturafenib · Pfizer · phase 1 · NCT05355701
- Sep 30, 2027regorafenib · Bayer · phase 4 · NCT02955940
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.